NTRK1 and non-small cell lung carcinoma: A pooled analysis of entrectinib in patients with NSCLC who had NTRK1 and ROS1 mutations demonstrated that 11 of 20 patients (55%) with baseline CNS metastases had a response, with median DOR of 12.9 months.